SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
Standard
SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature. / Marchiori, Elena; Rodionov, Roman N; Peters, Frederik; Magnussen, Christina; Nordanstig, Joakim; Gombert, Alexander; Spanos, Konstantinos; Jarzebska, Natalia; Behrendt, Christian-Alexander.
in: HEART FAIL CLIN, Jahrgang 18, Nr. 4, 10.2022, S. 609-623.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature
AU - Marchiori, Elena
AU - Rodionov, Roman N
AU - Peters, Frederik
AU - Magnussen, Christina
AU - Nordanstig, Joakim
AU - Gombert, Alexander
AU - Spanos, Konstantinos
AU - Jarzebska, Natalia
AU - Behrendt, Christian-Alexander
N1 - Copyright © 2022 Elsevier Inc. All rights reserved.
PY - 2022/10
Y1 - 2022/10
N2 - Fifty articles comprising 18 randomized controlled trials (RCTs), 16 observational studies, and 16 meta-analyses on the safety and effectiveness of sodium-glucose cotransporter 2 inhibitors were evaluated in the current review. Only one-fourth of the cohorts of recent trials had peripheral arterial disease (PAD), whereas this subgroup was at high risk for amputations. Despite a remarkable heterogeneity of RCTs, only 2 trials on canagliflozin suggested excess amputation rates, whereas several observational studies generated conflicting conclusions and remained short on possible explanations. Preliminary evidence from observational research suggested that patients with PAD may even benefit from SGLT-2 inhibitor treatment due to lower observed heart failure hospitalization rates.
AB - Fifty articles comprising 18 randomized controlled trials (RCTs), 16 observational studies, and 16 meta-analyses on the safety and effectiveness of sodium-glucose cotransporter 2 inhibitors were evaluated in the current review. Only one-fourth of the cohorts of recent trials had peripheral arterial disease (PAD), whereas this subgroup was at high risk for amputations. Despite a remarkable heterogeneity of RCTs, only 2 trials on canagliflozin suggested excess amputation rates, whereas several observational studies generated conflicting conclusions and remained short on possible explanations. Preliminary evidence from observational research suggested that patients with PAD may even benefit from SGLT-2 inhibitor treatment due to lower observed heart failure hospitalization rates.
KW - Canagliflozin
KW - Diabetes Mellitus, Type 2
KW - Glucose
KW - Humans
KW - Hypoglycemic Agents/pharmacology
KW - Sodium
KW - Sodium-Glucose Transporter 2 Inhibitors/pharmacology
U2 - 10.1016/j.hfc.2022.03.001
DO - 10.1016/j.hfc.2022.03.001
M3 - SCORING: Review article
C2 - 36216490
VL - 18
SP - 609
EP - 623
JO - HEART FAIL CLIN
JF - HEART FAIL CLIN
SN - 1551-7136
IS - 4
ER -